Evonik Evonik

X

Find Reparixin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Reparixin
Also known as: Repertaxin, 266359-83-5, Df 1681y, Df1681y, Reparixin (repertaxin), (r)-2-(4-isobutylphenyl)-n-(methylsulfonyl)propanamide
Molecular Formula
C14H21NO3S
Molecular Weight
283.39  g/mol
InChI Key
KQDRVXQXKZXMHP-LLVKDONJSA-N
FDA UNII
U604E1NB3K

Reparixin is an orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration, reparixin allosterically binds to CXCR1 and prevents CXCR1 activation by its ligand interleukin 8 (IL-8 or CXCL8). This may cause cancer stem cell (CSC) apoptosis and may inhibit tumor cell progression and metastasis. CXCR1, overexpressed on CSCs, plays a key role in CSC survival and the ability of CSC to self-renew; it is also linked to tumor resistance to chemotherapy. Inhibition of the IL-8/CXCR1 interaction also potentiates the cytotoxic effect of chemotherapeutic agents. In addition, reparixin inhibits CXCR2 activation and may reduce both neutrophil recruitment and vascular permeability during inflammation or injury.
1 2D Structure

Reparixin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide
2.1.2 InChI
InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
2.1.3 InChI Key
KQDRVXQXKZXMHP-LLVKDONJSA-N
2.1.4 Canonical SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C
2.1.5 Isomeric SMILES
C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C
2.2 Other Identifiers
2.2.1 UNII
U604E1NB3K
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (r)-2-(4-isobutylphenyl)propionylmethanesulfonamide

2. 2-(4-isobutylphenyl)propionylmethanesulfonamide

3. Df 1681y

4. Df-1681y

5. Df1681y

6. Reparixin Lysine

7. Reparixin Lysine Salt

8. Repertaxin

2.3.2 Depositor-Supplied Synonyms

1. Repertaxin

2. 266359-83-5

3. Df 1681y

4. Df1681y

5. Reparixin (repertaxin)

6. (r)-2-(4-isobutylphenyl)-n-(methylsulfonyl)propanamide

7. Df-1681y

8. Chembl191413

9. U604e1nb3k

10. 266359-83-5 (free Base)

11. Reparixin [inn]

12. (2r)-2-[4-(2-methylpropyl)phenyl]-n-methylsulfonylpropanamide

13. Reparixin [usan:inn]

14. Unii-u604e1nb3k

15. (2r)-2-(4-(2-methylpropyl)phenyl)-n-methylsulfonylpropanamide

16. 2-(4-isobutylphenyl)propionylmethanesulfonamide

17. Reparixin (usan/inn)

18. Reparixin [usan]

19. Reparixin [mart.]

20. Reparixin [who-dd]

21. Dsstox_cid_26509

22. Dsstox_rid_81678

23. Dsstox_gsid_46509

24. Gtpl8498

25. Schembl1884299

26. Zinc8717

27. Dtxsid6046509

28. Chebi:177765

29. Bcp10635

30. Ex-a2461

31. Tox21_112272

32. Bdbm50169045

33. Mfcd18633292

34. S8640

35. Ccg-267282

36. Cs-1379

37. Db12614

38. Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-n-(methylsulfonyl)-, (alphar)-

39. Ac-32023

40. Bs-16754

41. Hy-15251

42. Cas-266359-83-5

43. D08984

44. Q27088533

45. (2r)-2-[4-(2-methylpropyl)phenyl]-n-methylsulonylpropanamide

46. N-[(r)-2-(4-isobutyl-phenyl)-propionyl]-methanesulfonamide

47. Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-n-(methylsulfonyl)- (alphar)-

48. Benzeneacetamide, .alpha.-methyl-4-(2-methylpropyl)-n-(methylsulfonyl)-, (.alpha.r)-

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 283.39 g/mol
Molecular Formula C14H21NO3S
XLogP32.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count5
Exact Mass283.12421471 g/mol
Monoisotopic Mass283.12421471 g/mol
Topological Polar Surface Area71.6 Ų
Heavy Atom Count19
Formal Charge0
Complexity389
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Prevention of graft rejection


Treatment of coronavirus disease 2019 (COVID-2019)


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY